---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-002608"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T06:57:48.690439+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech: NCI-led Phase 2 study of PDS01ADC shows median PFS 9.6 months in mCRPC

## Summary
- Median PFS of 9.6 months (range 4.3-32.2) for PDS01ADC plus docetaxel in 3rd-line mCRPC patients.
- Median PSA decline of 40%; 6 of 16 patients achieved >50% PSA decline.
- Data presented at AACR special conference on prostate cancer (Boston, Jan 20-22, 2026).
- Study by NCI/NIH evaluating PDS01ADC synergy with docetaxel in advanced prostate cancer.

## SEC filing metadata
- accession: 0001140361-26-002608
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036126002608/0001140361-26-002608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036126002608/ef20064069_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-002608
- JSON: https://secwatch.observer/filing/0001140361-26-002608.json
- Plain text: https://secwatch.observer/filing/0001140361-26-002608.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.